Vaccines do not increase the risk of multiple sclerosis (MS) or other acquired central nervous system demyelinating syndromes (CNS ADS), according to a study published in JAMA Neurology.
Researchers sought to determine whether vaccines, particularly those for hepatitis B (HepB) and human papillomavirus (HPV), increased the risk of MS or other CNS ADS. They used a nested case-control study using data from the complete electronic health records of Kaiser Permanente Southern California (KPSC) members. Five controls per case were matched on age, sex, and zip code.
Patients with all forms of CNS ADS were analyzed using conditional logistic regression adjusted for race/ethnicity, health care utilization, comorbid diseases, and infectious illnesses before symptom onset.
Among the 780 cases of CND ADS and 3,885 controls, researchers found no association between HepB vaccination, HPV vaccination, or any vaccination and the risk of CNS ADS up to 3 years later. Vaccination of any type was associated with an increased risk of CNS ADS onset only within the first 30 days after vaccination and only in patients younger than 50 years.
These results show no longer-term association of vaccines with MS or any other CND ADS. The short-term increased risk suggests that vaccines may accelerate the transition from subclinical to overt autoimmunity in patients with existing diseases.
In this study, researchers reviewed vaccination records in order to determine whether vaccinations for hepatitis B and human papillomavirus increase the risk of multiple sclerosis and other central nervous system demyelinating syndromes.